Genmab (GMAB) shares climbed 3.5% in after-hours trade Monday after its Phase 3 EPCORE DLBCL-4 trial showed a 60% reduction in disease progression risk for relapsed lymphoma patients, a result that materially strengthens the bispecific antibody franchise co-developed with AbbVie.
The data arrive as biotech consolidation accelerates across the sector, and a chemotherapy-free regimen with this hazard ratio could broaden epcoritamab’s label and royalty streams at a time when large-cap acquirers are actively scouting best-in-class oncology assets.
Key Takeaways
- Trial met primary endpoint with hazard ratio of 0.40 in DLBCL
- GMAB after-hours gain of ~3.5% outpaced the broader biotech index
- Epcoritamab already approved in 65+ territories, expanding commercial base
Market Reaction & Context
GMAB added roughly 3.5% in after-hours trade on Monday, reaching approximately $26.94, compared with a regular-session close of $26.02. 1 That move outpaced the iShares Biotechnology ETF, which ended the session broadly flat, underscoring the stock-specific nature of the catalyst.
The EPCORE DLBCL-4 trial compared epcoritamab plus lenalidomide against standard-of-care chemotherapy in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had received at least one prior line of therapy. 2 DLBCL is the most common subtype of non-Hodgkin lymphoma, accounting for 25-30% of all cases globally and roughly 25,000 new U.S. diagnoses annually.
Trial Data in Detail
The study met its primary objective of progression-free survival, recording a hazard ratio of 0.40 (95% CI: 0.30-0.55), translating to a 60% reduction in the risk of disease progression or death versus the comparator arm. 1 Investigators described the improvement as both statistically significant and clinically meaningful.
Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously – a delivery route that distinguishes it from intravenous competitors and may support outpatient use, a selling point for payers and providers alike. The chemotherapy-free backbone of the regimen is notable given growing physician preference for reduced-toxicity protocols in second-line DLBCL.
Competitive Positioning & Consolidation Angle
The EPCORE DLBCL-4 result lands in a market where bispecific antibodies are rapidly displacing older chemotherapy combinations, and where Roche’s mosunetuzumab and Regeneron/Sanofi’s odronextamab are also competing for share. A hazard ratio of 0.40 in a chemotherapy-free doublet, if confirmed in peer-reviewed data, would represent a competitive benchmark that rivals will need to address.
From a macro M&A perspective, Genmab has previously attracted deal speculation given its deep antibody engineering pipeline and co-promotion infrastructure with AbbVie. Positive Phase 3 data in the world’s largest lymphoma subtype reinforces the franchise’s standalone value – and raises the strategic cost for any potential acquirer. The epcoritamab programme already holds regulatory approvals in more than 65 territories under the brand names EPKINLY in the U.S. and Japan, and TEPKINLY in the EU. 1
Outlook & Management Commentary
Genmab and AbbVie said they plan to engage global regulatory authorities on the basis of the topline results, with detailed data to be presented at a future medical meeting. 1 No timeline for a supplemental regulatory submission was provided.
“The study met its primary objective, demonstrating a 60% reduction in the risk of disease progression and death,” the companies said in disclosing the topline results, adding that the improvement was both statistically significant and clinically meaningful.
Under the co-development agreement, Genmab and AbbVie share commercial responsibilities in the U.S. and Japan, while AbbVie handles broader global commercialization. A label expansion into earlier lines of DLBCL therapy would widen the addressable patient pool and, consequently, the royalty base flowing to Genmab.
Conclusion
The EPCORE DLBCL-4 data represent a material inflection for the epcoritamab franchise, confirming efficacy in a large and commercially significant patient population with a chemotherapy-free combination. 2 For macro and sector investors tracking biotech consolidation, the trial outcome sharpens Genmab’s competitive moat and elevates the strategic calculus around the company’s pipeline value ahead of any regulatory engagement.
Not investment advice. For informational purposes only.
References
1Luke Juricic (June 29, 2026). “Genmab stock rises on positive lymphoma trial results”. Investing.com. Retrieved June 30, 2026.
2WSJ Business News (June 30, 2026). “Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial”. X (formerly Twitter) / The Wall Street Journal. Retrieved June 30, 2026.